Hep Voice July - September 2025

Welcome to Hep Voice!

As we reflect on World Hepatitis Day 2025 and its rallying call to “break it down”, this issue of Hep Voice shows how our community is doing exactly that – breaking down barriers of stigma, inequity, and inaction to drive progress toward elimination.

You’ll find highlights from this year’s World Hepatitis Day, where members and partners across the globe mobilised to raise awareness, demand action, and amplify the voices of people living with hepatitis. The reach and creativity of these efforts remind us what’s possible when wecome together. The path to elimination relies on prevention.

On page 24, we introduce SAFEStart+, a bold new initiative to protect babies from preventable diseases like hepatitis B, while on page 22 we share a new hepatitis A briefing designed to equip advocates with the knowledge and tools to respond to a shifting landscape.

At the heart of elimination is community leadership, so in this edition we spotlight powerful examples from End Hep C SF in the United States, HealthDrive Nigeria, and United Way Mumbai, each showing how lived experience and grassroots action are driving change on the ground.

Looking ahead, November marks the second World Hepatitis Testing Week, a vital chance to build on last year’s momentum and keep testing high on the global agenda. And with the World Hepatitis Summit 2026 fast, approaching, now is the time to secure your place at this pivotal event.

Together, by breaking down barriers and standing united, we can achieve a world free from hepatitis.

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close